Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

Recent News and Articles on the Keywords: levosimendan + survive + compared  Related to the article below (Last Update: 12/1/2008)

News results: Standard Version | Text Version | Image Version

Browse Top Stories Recent Last hour Last day Past week Past month Archives All dates Blogs News Alerts RSS | Atom About Feeds Your search - levosimendan + survive + compared - did not match any documents. Suggestions: Make sure all words are spelled correctly. Try different keywords. Try more general keywords. Try fewer keywords. Try Google Blog Search. Also, you can browse today's headlines on the Google News homepage.

Recent News and Articles on the Keywords: 0.34 + web + 111  Related to the article below (Last Update: 8/7/2008)

Sun Healthcare Group, Inc. Reports Second Quarter Earnings ... Trading Markets (press release), CA - Any documents filed by Sun with the SEC may be obtained free of charge at the SEC's web site at www.sec.gov. In addition, investors and stockholders of Sun ...SUNH Cisco Reports Fourth Quarter and Fiscal Year 2008 Earnings CNNMoney.com - Aug 5, 2008 We believe we are entering the next phase of the Internet as growth and productivity will center on collaboration enabled by networked Web 2.0 technologies. ...CSCO Plum Creek Timber Company, Inc. Reports Results for Second Quarter ... MarketWatch - Jul 28, 2008 A live webcast of the conference call may be accessed through Plum Creek's Web site at www.plumcreek.com by clicking on the "Investors" link. ...PCL SAP Reports Strong Growth in Software and Software-Related Service ... FOXBusiness - Jul 29, 2008 US GAAP earnings per share from continuing operations for the second quarter of 2008 was 0.34 euro (2007: 0.37 euro), which was a decrease of 8% compared to ...SAP - AG - OTC:CMTX WELT ONLINE Nara Bancorp Reports $0.07 Earnings Per Diluted Share for Second ... WELT ONLINE, Germany - Jul 22, 2008 The allowance for loan losses to non-performing loans was 111%, 121% and 121% at June 30, 2008, December 31, 2007 and March 31, 2008, respectively. ... First Defiance Announces 2008 Second Quarter Earnings PR Newswire (press release) First Place Financial Corp. Reports Quarterly Net Income of $2.9 ... Trading Markets (press release) Wachovia Details 2nd Quarter Loss; Outlines Initiatives to ... PR Newswire (press release) all 1,034 news articles »  FDEF - FPFC - NARA Copper Mountain Mining Corporation - Exploration Update: Near ... Canada NewsWire (press release), Canada - Jul 16, 2008 Additional information is available on the Company's web page at www.CuMtn.com. On behalf of the Board of COPPER MOUNTAIN MINING CORPORATION "Peter Holbek" ...CVE:CUM Amazon.com Announces Second Quarter Sales up 41% to $4.06 Billion ... Trading Markets (press release), CA - Jul 23, 2008 Over 400000 developers have registered to use Amazon Web Services (AWS), up more than 30000 from last quarter. -- AWS released a new family of instance ...AMZN CenterPoint Energy Reports Second Quarter 2008 Earnings RedOrbit, TX - A copy of that report is available on the company's Web site, www.CenterPointEnergy.com, under the Investors section. Other filings the company makes at the ...CNP Outokumpu's second quarter 2008 interim report - improved ... Ad-Hoc-News (Pressemitteilung), Germany - Jul 24, 2008 Earnings pershare totaled EUR 0.31 (I/2008: EUR 0.35) and earnings per share fromcontinuing operations totaled EUR 0.72 (I/2008: EUR 0.34). ...HEL:OUT1V

The SURVIVE trial failed to demonstrate benefits of Levosimendan compared with Dobutamine on survival in acute decompensated heart failure

Although acutely decompensated heart failure is a very common cause of hospitalization, most treatments commonly used have not been validated in large randomized clinical trials.
Inotropic agents currently used for acute heart failure, including Dobutamine, Milrinone, and Nesiritide, have been associated with an increased risk of mortality.

Levosimendan ( Simdax ) is a new agent that induces calcium sensitization for positive inotropic effect and activates vascular smooth-muscle ATP-dependent potassium channels for vasodilatation. The resulting improvement of cardiac function and blood flow may provide a hemodynamic support in patients with acutely decompensated heart failure.

The SURVIVE trial was designed to test the effect of Levosimendan against Dobutamine on death and major clinical events among patients hospitalized for acutely decompensated heart failure.

SURVIVE-W was a double-blind, active control, double dummy, randomized clinical trial.
Patients were eligible for inclusion if they had acutely decompensated heart failure, left ventricular ejection fraction <30%, and a clinical need for intravenous inotropic support, as evidenced by an insufficient response to intravenous diuretics and/or vasodilators and at least one of the following:

1) oliguria ( mean urine output <30 mL/h for at least 6 h ) not due to hypovolemia,
2) persistent dyspnea at rest,
3) mechanical ventilation for heart failure, or
4) invasive hemodynamic demonstration of a pulmonary wedge pressure ( 18 mm Hg and/or cardiac index =2.2 L/(min · m2 ).

A total of 1327 patients were randomized to receive either Dobutamine [ minimum dose 5 µg/( kg · min ) for at least 2 h ] or Levosimendan [12-µg/kg bolus followed by 0.2 µg/( kg · min ) ].

The primary end point was all cause mortality within 180 days.

The incidence of the primary end point was 26% in the Levosimendan group and 28% in the Dobutamine group ( hazard ratio [HR] 0.91 ).
No differences were observed in the incidence of the secondary end point, all-cause mortality within 31 days ( 12% vs 14% for Levosimendan and Dobutamine, respectively, HR 0.85 ).

A post hoc analysis evaluating all-cause mortality within 5 days showed a trend in favor of Levosimendan ( 4% vs 6%, HR 0.72 ).
The trend was stronger among patients with a history of heart failure ( HR 0.58 ).